The fallback is now the traditional chemotherapeutic use of bisantrene using the RC220 formulation. This has real value beyond AML, but is relatively minor compared to the FTO and cardioprotection opportunities.
Don't presume anything in regards not being able to sell the same drug for different indications to different companies for the same geography. I put a great deal of effort into this question before I left RAC.
FTO is probably easier to validate than cardioprotection, but if you run the right trials you can validate both at the same time.
The highest return on equity for small biotechs is achieved after Phase 2 validation. Race is a little more complex as we have a drug with multiple major opportunities, rather than a pipeline of different drugs. Bisantrene is probably closer to something like aspirin with its multiple different uses than the usual oncology drug. Makes for a complex commercialisation strategy.
Yes like you I hope we get an extensive update with all the details required for us to understand the preclinical, clinical and commercial strategy.
RAC Price at posting:
$1.32 Sentiment: Buy Disclosure: Held
(20min delay)